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Antibodies 14F7 and the corresponding
anti-idiotype 1E10 (racotumomab, mis-
spelled as racotumumab) were mistak-
enly conflated in this review. 14F7 reacts
with (Neu5Gc)GM3, was recently human-
ized (1), but has not yet been tested
in clinical trials. Racotumomab induced
a human anti-(Neu5Gc)GM3 immune
response, which correlated with longer
median survival in non-small cell lung can-
cer (2). The first clinical trial result using
racotumomab was actually published in
2002 (3). A phase III trial testing racotu-
momab in advanced non-small cell lung
cancer began in 2011, and is currently
recruiting (NCT01460472). These studies
do not consider dietary Neu5Gc intake
and incorporation as a variable that could
affect (Neu5Gc)GM3 expression by human
cancers.
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